Tech Company Financing Transactions
Immunomic Therapeutics Funding Round
Immunomic Therapeutics secured a $3 million venture capital round on 7/17/2013. Investors included private investors.
Transaction Overview
Company Name
Announced On
7/17/2013
Transaction Type
Debt
Amount
$3,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company will use the proceeds to advance a cedar-pollen allergy vaccine and a new peanut-allergy vaccine toward commercialization.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
15010 Broschart Rd. 250
Hershey, MD 20850
USA
Hershey, MD 20850
USA
Phone
Website
Email Address
Overview
Immunomic Therapeutics, Inc. is developing next generation vaccines focusing on allergy immunotherapy. The Company's first vaccine will be for Japanese Red Cedar, JRC-LAMP-vax.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
William Hearl
Chief Financial Officer
Eric Winzer
Chief Scientific Officer
Teri Heiland
Vice President
Andrew Eisen
VP - Bus. Development
Sia Anagnostou
VP - Operations
Timothy Coleman
VP - Regulatory Affairs
Louise Peltier
Browse more venture capital transactions:
Prev: 7/17/2013: Markerly venture capital transaction
Next: 7/17/2013: Grovo venture capital transaction
Share this article
Where The Data Comes From
We do our best to record all VC transactions involving tech companies. All VC database entries reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs